Post-transplant lymphoproliferative disorder (PTLD) is a complication of allogeneic bone marrow transplantation (BMT). Rare cases of PTLD after autologous BMT have been reported only in adults. This case report is the first to describe PTLD in a pediatric patient after autologous peripheral stem cell transplantation (PSCT). This 2-year-old male with stage IV neuroblastoma underwent autologous PSCT. The post-PSCT course was complicated by fever with hematochezia and a lung mass. On day 94 post PSCT, colonoscopy revealed an ulcer due to a PTLD, monomorphic type, B cell phenotype, associated with Epstein-Barr virus. Fine needle aspiration identified the lung mass as neuroblastoma. PTLD can occur in pediatric autologous PSCT recipients, and may occur more frequently in autologous grafts manipulated by T cell depletion or CD34 + cell selection. Bone Marrow Transplantation (2000) 26, 1021-1024. Keywords: hematopoietic stem cell transplantation; autologous transplantation; lymphoproliferative disorders; herpesvirus; child Post-transplant lymphoproliferative disorder (PTLD) is a complication in bone marrow transplantation (BMT). 1 PTLD is more frequently associated with allogeneic BMT, particularly with immunosuppressive therapy for graft-versus-host disease or T cell-depleted marrow grafts. Autologous BMT or peripheral stem cell transplantation (PSCT) is less immunosuppressive than allogeneic BMT. There are only rare reports of PTLD following autologous BMT or PSCT, all of which occurred in adults. [2] [3] [4] [5] [6] [7] [8] This case report describes the first pediatric patient with an autologous PSCT to develop a PTLD associated with Epstein-Barr virus (EBV). 
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PTLD is more frequently associated with allogeneic BMT, particularly with immunosuppressive therapy for graft-versus-host disease or T cell-depleted marrow grafts. Autologous BMT or peripheral stem cell transplantation (PSCT) is less immunosuppressive than allogeneic BMT. There are only rare reports of PTLD following autologous BMT or PSCT, all of which occurred in adults. [2] [3] [4] [5] [6] [7] [8] This case report describes the first pediatric patient with an autologous PSCT to develop a PTLD associated with Epstein-Barr virus (EBV). 
Materials and methods
Clinical information was obtained retrospectively from medical records. Endoscopic biopsy tissues were placed in Bouin's fixative and submitted for routine processing. Paraffin-embedded 4 m thick tissue sections were prepared and stained with hematoxylin-eosin for light microscopic evaluation. Paraffin section immunohistochemistry and EBV encoded RNA (EBER) in situ hybridization studies were performed using previously described methods. 9 Positive controls for EBER in situ hybridization and EBV latent membrane protein (LMP-1) immunohistochemistry stains included sections from a lymph node biopsy containing mixed cellularity Hodgkin's disease prepared with Bouin's fixative which demonstrated appropriate staining of ReedSternberg cells. PTLD was classified using previously described criteria.
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Case history
A male child presented at age 21 months with stage IV neuroblastoma involving the left adrenal gland, left neck and axillary lymph nodes, and the right orbit. He was treated according to the Memorial Sloan-Kettering Protocol 7 with a total of six cycles of chemotherapy consisting of cyclophosphamide/vincristine/adriamycin alternated with cisplatin/VP-16. Six months after diagnosis, the adrenal mass was completely resected, followed by resection of the residual left neck mass, which demonstrated neuroblastoma. One month later, an autologous PSCT was performed. The preparative regimen consisted of carboplatin, VP-16 and melphalan. The patient received an unmanipulated, unpurged peripheral blood stem cell graft containing 182 × 10 9 mononuclear cells/kg and 4.6 × 10 6 CD34 cells. The CD3 cell dose was not determined. The patient demonstrated engraftment on day 11. Seventy days after transplant, he developed persistent high fever, followed by hematochezia. The endoscopic examination on day 94 revealed ulcers in the duodenum and colon. The cecum and descending colon each contained a single edematous ulcer ( Figure 1 ). The rectum contained scattered superficial ulcers. The stomach, duodenum, and colon biopsies demonstrated cytomegalovirus (CMV) infection. In addition, the colon biopsy demonstrated features consistent with PTLD. The peripheral blood contained 30289 copies/ml cytomegalovirus DNA, while EBV DNA was not evaluated. Therapy with gancyclovir was initiated. There were no other clinical manifestations of lymphoproliferative disease. Further evaluation included only a chest X-ray and chest CT scan, which revealed a mass in the right lung, with no lymphadenopathy. A fine needle aspiration of the right lung mass contained neuroblastoma. The patient was discharged with no more therapy, and expired on day 133 post PSCT.
Pathology examination
The colon biopsy contained a prominent lymphoid infiltrate expanding the lamina propria representing a PTLD. The PTLD had morphologic features of a large cell lymphoma ( Figure 2 ). Immunohistochemistry studies demonstrated a B cell phenotype in the large lymphocytes exhibited by positive immunoreactivity for CD20 (Figure 3 ), while CD3 and CD45RO were negative. An immunohistochemistry stain for EBV LMP-1 was negative. EBER was detected in the large lymphocytes by in situ hybridization (Figure 4 ). This case could also be classified as a PTLD, of monomorphic type and with a B cell phenotype. 10 
Discussion
PTLD has been reported in a small number of cases after autologous BMT or PSCT in adults (Table 1) . This is the first case report of PTLD following autologous PSCT in a pediatric patient.
These cases of PTLD indicate a significant level of immune suppression after autologous transplantation. Five of these adult cases with PTLD had additional manipulation of the autologous graft prior to transplantation ( Table 1) . Manipulation of the autologous BMT or PSCT grafts may result in increased immune suppression and delay in immune system recovery post transplant (ie T cell purge, B cell purge, CD34 + cell selection), 3, 4, 8, 11 as well as increased risk for development of PTLD. However, PTLD also occurred in three adult autologous transplant patients that were not reported to have additional manipulation of the stem cell collection product.
In these autologous transplant patients, PTLD occurred within 1 to 3 months after transplantation ( Table 1) . The development of PTLD in the early post-transplant period appears similar to allogeneic BMT. However, PTLD in allogeneic BMT occurs frequently up to 7 months post transplant 9 The earlier development of PTLD within the first 3 months in autologous transplant patients may reflect earlier immune system recovery.
The pathologic features of PTLD in autologous transplant recipients are similar to those in allogeneic BMT patients. The PTLDs after autologous BMT or PSCT all contain EBV and have a B cell phenotype (Table 1) , [2] [3] [4] [5] [6] [7] [8] as in allogeneic BMT. 9 Similarly, the morphologic types of PTLD were variable in the autologous transplant patients (polymorphic 3; polymorphic with focal monomorphic 1; monomorphic 5).
The outcome in these autologous transplant patients with PTLD was poor. Six of the eight (75%) previously reported cases died due to PTLD (Table 1) . [2] [3] [4] [5] [6] [7] [8] PTLD type (polymorphic vs monomorphic) does not appear to be predictive of outcome since two of the three cases of polymorphic PTLD and the case of polymorphic with focal monomorphic PTLD had died. This poor outcome in PTLD of variable morphologic types is similar to allogeneic BMT. 9 
Bone Marrow Transplantation
Treatment of the PTLDs in these autologous transplant patients was variable (Table 1 ) and included mostly the antiviral agent acyclovir, immune globulin, steroids and interferon; while two patients received chemotherapy such as methotrexate, leucovorin, or vincristine. Recently, allogeneic BMT patients have been managed with infusions of donor leukocytes for prophylaxis or treatment of PTLD, 12 or EBV specific donor T cells. 13 Also, monoclonal antibodies to B cell antigens have been utilized successfully in small numbers of allogeneic BMT patients.
14 However, these treatment methods have not been applied to PTLD in autologous transplant recipients. For autologous BMT or PSCT recipients, infusion of stored autologous T cell lymphocytes may be another potentially useful technique for treatment of PTLD or other complications of immune suppression after autologous transplantation. Recently, encouraging results have been obtained utilizing a chimeric monoclonal antibody to CD20 (rituximab) to treat a few cases of PTLD, which are typically CD20 positive. 15, 16 As described in this report, PTLD is typically associated with EBV. Frequently, children are negative for prior exposure to EBV by serologic tests. In children that have undergone PSCT or solid organ transplantation, development of PTLD is likely associated with primary EBV infection of host cells in many cases. While in EBV-negative children who have undergone allogeneic BMT, development of PTLD may be associated with reactivation of EBV in donor cells, in solid organ transplantation, EBV-negative children have a higher incidence of PTLD. 17 For this case, it is not known whether this PTLD is associated with pri-mary EBV infection or reactivation since serologic tests were not performed prior to autologous PSCT. Also, the endoscopic biopsy specimens containing PTLD were not sufficient for additional special studies to evaluate EBV. Further studies in children for EBV status prior to BMT and PSCT may be helpful in identifying increased risk for PTLD.
An additional unique feature in this case was the simultaneous occurrence of CMV infection documented in the duodenum biopsies. Concurrent CMV infection was not reported in any of the previous cases of PTLD in autologous BMT or PSCT recipients, 2-8 although one case was reported to have prior CMV pneumonitis. 7 For cases of PTLD in allogeneic BMT, a review of previous reports revealed concurrent CMV infection in five of 58 cases (8.6%) 9 and another case with prior CMV infection, typically manifest as CMV pneumonitis. In solid organ transplant recipients, CMV infection has been reported to be associated with PTLD. 17 CMV infection indicates a significant level of immunosuppression and has been suggested to be additionally immunosuppressive and an increased risk factor for development of PTLD. 17 For this case report, it is not known whether this CMV infection represents a primary infection or reactivation since serologic tests were not performed prior to autologous PSCT. Also, there was no post-transplant evaluation of T cell levels or function in this patient.
In conclusion, PTLD can occur in autologous BMT or PSCT recipients including pediatric patients. PTLD may occur more frequently in autologous transplants manipulated with T cell depletion or CD34 + cell selection due to the increased immune suppression and subsequent delayed immune system recovery. Post-transplant CMV infection and primary exposure to EBV may also contribute to increased frequency of PTLD. Outcome of PTLD in autologous BMT or PSCT patients is poor. Increased suspicion for PTLD in these transplant patients at increased risk may allow earlier diagnosis, earlier initiation of therapy, establishment of a standard treatment regimen, and improved outcome.
